Research article summary (published 29 Jun 2009):

Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.

Full Abstract

OBJECTIVES: Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy. METHODS: Six Hoehn and Yahr stage III patients underwent 123I-FP-CIT imaging prior to, 3 months, and 1 year after the onset of nicotine therapy. Nicotine was administered transdermally with increasing daily doses during 3 months (up to 105 mg/day) and decreased progressively. On co-registered magnetic resonance imaging, striatal regions of interest were drawn and binding potentials of 123I-FP-CIT were calculated.Changes in Unified Parkinson's Disease Rating Scale-III over time were compared with binding potentials using regression analysis. RESULTS: All patients improved motor scores at 3 months (-65 +/- 22% 'off', -89 +/- 12% 'on') and most received fewer dopaminergic drugs (-30% dosage in average). Motor improvement persisted to a lesser extent at 1 year(-39 +/- 31% 'off', -13 +/- 43% 'on'), partly because one patient stopped the treatment. Interestingly, the decrease in binding potentials (-4.0 +/- 10.5%) was slower than that expected in Parkinsonian patients (usually -10% per year) and was inversely correlated with Unified Parkinson's Disease Rating Scale-III improvement, r= 0.83 'off' and 0.91 'on'. CONCLUSION: This observational study emphasizes a potential effect of nicotine therapy on striatal dopamine transporter density, which may be interpreted as direct pharmacological effect or deceleration of neuronal loss.

Author information

Author/s: Itti, Emmanuel (E); Villafane, Gabriel (G); Malek, Zoulikha (Z); Brugières, Pierre (P); Capacchione, Daniela (D); Itti, Laurent (L); Maison, Patrick (P); Cesaro, Pierre (P); Meignan, Michel (M);

Affiliation: Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti(-atsign-)hmn.aphp.fr

Journal and publication information

Publication Type: Clinical Trial; Journal Article

Journal: Nuclear medicine communications (Nucl Med Commun), published in England. (Language: eng)

Reference: 2009-Jul; vol 30 (issue 7) : pp 513-8

Dates: Created 2009/06/10; Completed 2009/08/24;

PMID: 19451839, status: MEDLINE (last retrieval date: 8/24/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Administration, Cutaneous Dopamine Plasma Membrane Transport Proteins - analysis; metabolism Dose-Response Relationship, Drug Humans Magnetic Resonance Imaging Male Middle Aged

Neostriatum - drug effects; physiopathology Nicotine - administration & dosage; therapeutic use Parkinson Disease - drug therapy; metabolism; radionuclide imaging Regression Analysis Time Factors Tomography, Emission-Computed, Single-Photon Tropanes - diagnostic use

Associated Chemicals: Dopamine Plasma Membrane Transport Proteins (0) ; Tropanes (0) ; 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane (155797-99-2) ; Nicotine (54-11-5)

Related articles

These are the highest related articles currently in the database:

• Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. 29 Nov 2006
• Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. 11 Feb 2006
• [Neuroimaging of the dopamine transporter in Parkinsons disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil] 30 Aug 2006
• Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. 30 Oct 1997
• Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? 30 Oct 2005
• Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. 29 Jun 1998
• Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. 30 Jan 2004
• Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. 20 Feb 2005
• The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease. 6 Sep 2005
• Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. 30 Aug 1998

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.